Clinical Trial Participation Linked to Longer OS in Platinum-Resistant Ovarian Cancer

March 27, 2023 9:42 am

by Jessica Nye, PhD

Patients with platinum-resistant epithelial ovarian cancer may have better overall survival (OS) if they enroll on a clinical trial than if they receive standard care, according to study results presented at the 2023 SGO Annual Meeting … Read more

Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer

March 27, 2023 9:13 am

by Devin McLaughlin

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Researchers observed favorable surgical outcomes — even … Read more

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 27, 2023 9:11 am

by Jason Harris

Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1Read more

FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer

November 14, 2022 12:21 pm

By Kristi Rosa

The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior … Read more

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial

October 27, 2022 2:26 pm

Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.

Presenting results from the … Read more

Hannah C. Karpel, MS, Talks Increasing Clinical Trial Accrual in Patients With Gynecologic Malignancies Following NCI Call-to-Action

October 4, 2022 10:04 am

by Ariana Pelosci

A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.

A recent single-institution study presented

Read more

ASCO Addresses PARP Controversy in Guideline Update

September 28, 2022 12:01 pm

— A response to “practice-changing data” in the first- and second-line setting

by Mike Bassett

An updated recommendation from the American Society of Clinical Oncology (ASCO) warns against the routine use of PARP inhibitor monotherapy in the second- or later-line

Read more

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15, 2022 10:45 am

by Kristi Rosa

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

Maintenance treatment with niraparib (Zejula) produced a sustained and

Read more

Phase 1 Success of Targeting MUC16 in Patients With Recurrent Ovarian Cancer

September 14, 2022 1:11 pm

by Jordyn Sava

In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.

Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more

TCR T-Cell Therapy Shows Efficacy Across MAGE-A4+ Solid Tumors

September 10, 2022 10:50 am

by Victoria Johnson

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including

Read more

Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials

September 9, 2022 10:37 am

by Mike Bassett

— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib

PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more

Study Finds Genetic Counseling for Breast, Ovarian Cancer Syndrome Did Not Significantly Increase with Clinician Support

August 15, 2022 11:11 am

by Erin Hunter

Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.

A new study shows that access to clinician

Read more

MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

First-Line Rucaparib Maintenance Improves PFS in Ovarian Cancer, Regardless of HRD Status

June 6, 2022 9:30 am

by Ariana Pelosci

The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.

Rucaparib (Rubraca) significantly improved progression-free survival

Read more

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

June 5, 2022 9:55 am

by Caroline Hopkins

CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.

The drug, which AstraZeneca licensed from Merck in … Read more

A Behind-the-Scenes Look at My Cancer Clinical Trial Experience

June 1, 2022 11:07 am

by Kelly Irvin

It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.

To find clinical trials, please check out the Read more

First-line Niraparib Improves PFS in Ovarian Cancer

May 18, 2022 9:16 am

by Ariana Pelosci

An individualized starting dose of niraparib, determined by weight and platelet count continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status.

An

Read more

MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer: What Next?

April 25, 2022 12:08 pm

by Rachel N. Grisham, M.D.

As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs … Read more

Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian Cancer

April 13, 2022 2:12 pm

by Conor Killmurray

Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.

The use of dual immune checkpoint

Read more

Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses

April 12, 2022 1:12 pm

by Alison Kanski

NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more